DE69328025D1 - Dorsalgewebe beeinflussender faktor und zusammensetzungen - Google Patents

Dorsalgewebe beeinflussender faktor und zusammensetzungen

Info

Publication number
DE69328025D1
DE69328025D1 DE69328025T DE69328025T DE69328025D1 DE 69328025 D1 DE69328025 D1 DE 69328025D1 DE 69328025 T DE69328025 T DE 69328025T DE 69328025 T DE69328025 T DE 69328025T DE 69328025 D1 DE69328025 D1 DE 69328025D1
Authority
DE
Germany
Prior art keywords
compositions
influencing factor
dorsal tissue
factors
tissue influencing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69328025T
Other languages
English (en)
Other versions
DE69328025T2 (de
Inventor
M Valenzuela
M Harland
Y Ip
C Smith
D Yancopoulos
Henryk Cudny
Teresa Lamb
Anne Knecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Regeneron Pharmaceuticals Inc
Original Assignee
University of California
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Regeneron Pharmaceuticals Inc filed Critical University of California
Application granted granted Critical
Publication of DE69328025D1 publication Critical patent/DE69328025D1/de
Publication of DE69328025T2 publication Critical patent/DE69328025T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69328025T 1992-09-03 1993-09-02 Dorsalgewebe beeinflussender faktor und zusammensetzungen Expired - Lifetime DE69328025T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93995492A 1992-09-03 1992-09-03
US95041092A 1992-09-23 1992-09-23
US95740192A 1992-10-06 1992-10-06
PCT/US1993/008326 WO1994005791A2 (en) 1992-09-03 1993-09-02 Dorsal tissue affecting factor and compositions

Publications (2)

Publication Number Publication Date
DE69328025D1 true DE69328025D1 (de) 2000-04-13
DE69328025T2 DE69328025T2 (de) 2000-11-02

Family

ID=27420696

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69328025T Expired - Lifetime DE69328025T2 (de) 1992-09-03 1993-09-02 Dorsalgewebe beeinflussender faktor und zusammensetzungen

Country Status (9)

Country Link
US (4) US5843775A (de)
EP (1) EP0656062B1 (de)
JP (1) JP3431153B2 (de)
AT (1) ATE190352T1 (de)
AU (1) AU676847B2 (de)
DE (1) DE69328025T2 (de)
HK (1) HK1008347A1 (de)
IL (2) IL134656A (de)
WO (1) WO1994005791A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL134656A (en) * 1992-09-03 2006-12-10 Univ California Antibodies that bind the polypeptide nogin and hybridoma capable of producing these antibodies
US5679783A (en) * 1994-11-22 1997-10-21 The Regents Of The University Of California DNA encoding a tissue differentiation affecting factor
US6133232A (en) * 1996-06-20 2000-10-17 The Regents Of The University Of California Endoderm, cardiac and neural inducing factors
WO1998033918A1 (en) * 1997-02-05 1998-08-06 The Regents Of The University Of California Morphogenic proteins
WO1998037195A1 (en) * 1997-02-19 1998-08-27 Regeneron Pharmaceuticals, Inc. Morphogenic proteins
US6075007A (en) * 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
WO1999061044A1 (en) * 1998-05-28 1999-12-02 The Board Of Trustees Of The University Of Arkansas Noggin and antagonists of bone morphogenetic proteins to suppress pathologic bone resorption
US6087168A (en) 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
WO2000064460A2 (en) * 1999-04-23 2000-11-02 Sulzer Orthopedics Ltd. Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin
WO2001098463A1 (en) * 2000-06-20 2001-12-27 Es Cell International Pte Ltd Method of controlling differentiation of embryonic stem (es) cells by culturing es cells in the presence of bmp-2 pathway antagonists
EP1357828A2 (de) * 2001-01-12 2003-11-05 University of Medicine and Dentistry of New Jersey Knochenmorphogenetisches protein-2 bei der behandlung und diagnose von krebs
WO2002087632A1 (en) * 2001-05-02 2002-11-07 Metaprobe, Inc. High throughput screening methods using magnetic resonance imaging agents
US20030134790A1 (en) * 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
GB2385052A (en) * 2002-02-05 2003-08-13 Leuven K U Res & Dev Treatment of spondyloarthropathies
WO2007028212A1 (en) * 2005-09-08 2007-03-15 Apollo Life Sciences Limited Noggin and chimeric molecules thereof
KR101163171B1 (ko) * 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
WO2010147803A2 (en) * 2009-06-08 2010-12-23 Regents Of The University Of Michigan Adult cerebellum-derived neural stem cells and compositions and methods for producing oligodendrocytes
EP3021945A4 (de) * 2013-07-18 2017-06-07 Ann and Robert H. Lurie Children's Hospital of Chicago Zusammensetzungen und verfahren zur detektion und behandlung von neuralrohrdefekten
WO2015134770A1 (en) * 2014-03-07 2015-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treating soft tissue via controlled drug release
AT521641B1 (de) * 2018-09-12 2020-07-15 Fianostics Gmbh Verfahren zur Diagnose von Lebererkrankungen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0491675A1 (de) * 1984-01-30 1992-06-24 Imperial Cancer Research Technology Limited Verbesserungen an Wachstumfaktoren
JPS62502589A (ja) * 1985-04-11 1987-10-08 ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン フオン・ビルブラント因子
US5030576A (en) * 1986-04-30 1991-07-09 Genentech, Inc. Receptors for efficient determination of ligands and their antagonists or agonists
US4857637A (en) * 1986-05-07 1989-08-15 Genentech, Inc. Methods and compositions for immunologically modulating growth hormone receptor activity
US5219759A (en) * 1987-04-22 1993-06-15 Chiron Corporation Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5177197A (en) * 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
ATE140966T1 (de) * 1990-09-25 1996-08-15 Genentech Inc Neuer neurotropischer faktor
US5364769A (en) * 1990-09-25 1994-11-15 Genentech, Inc. Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
JP4124815B2 (ja) * 1991-10-31 2008-07-23 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ＴＧＦ−β型受容体ｃＤＮＡおよびその用途
WO1993009229A1 (en) * 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
IL134656A (en) * 1992-09-03 2006-12-10 Univ California Antibodies that bind the polypeptide nogin and hybridoma capable of producing these antibodies

Also Published As

Publication number Publication date
JP3431153B2 (ja) 2003-07-28
US5821124A (en) 1998-10-13
IL134656A (en) 2006-12-10
EP0656062B1 (de) 2000-03-08
US6277593B1 (en) 2001-08-21
WO1994005791A3 (en) 1994-07-07
ATE190352T1 (de) 2000-03-15
US20020102643A1 (en) 2002-08-01
AU676847B2 (en) 1997-03-27
DE69328025T2 (de) 2000-11-02
IL106894A0 (en) 1994-05-30
WO1994005791A2 (en) 1994-03-17
EP0656062A1 (de) 1995-06-07
JPH08504086A (ja) 1996-05-07
HK1008347A1 (en) 1999-05-07
US5843775A (en) 1998-12-01
AU4846593A (en) 1994-03-29

Similar Documents

Publication Publication Date Title
DE69328025T2 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
DE69819167D1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
IL143748A0 (en) Substituted aryl or heteroarylamides having retinoid-like biological activity
EE200000318A (et) Uudsed ühendid
SE9704546D0 (sv) Novel compounds
ES8702431A1 (es) Procedimiento para preparar una proteina inhibidora de la coagulacion de la sangre
DE3870508D1 (de) Zusammensetzung zur behandlung des haares.
DE69019345D1 (de) Zusammensetzung zur behandlung von samen.
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
KR0180256B1 (en) Bpc peptides, their preparation and use
DE69425820D1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
NO175313C (no) Joderte polymerer og deres anvendelse
DE68911132D1 (de) Hematopoietische kolonien stimulierende faktoren zur verbesserung des lipoprotein/cholesterin-profils.
IL139604A0 (en) Novel peptides
MX9700624A (es) Azolidinonas de imidazopiridina.
DE69002558D1 (de) Zusammensetzungen und methoden zur verhinderung von inkrustierungen.
DK0633928T3 (da) Mikroorganismer, deres fremstilling og anvendelse
DE69408394D1 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
DE68913995D1 (de) Zusammensetzung zur behandlung progressiver myopie.
CA2143442A1 (en) Dorsal tissue affecting factor and compositions
DE69202842D1 (de) Verbessertes Herzstück und Verfahren zur dessen Herstellung.
DE69007028D1 (de) Verfahren zur Herstellung von 3,4-Epoxybutyrat und Zwischenprodukte dafür.
IL124354A0 (en) Hemoregulatory compounds
EP0412941A3 (en) Phospholipids for the treatment of multiple sclerosis
DE69729098D1 (de) Fluorierung von ketoamiden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition